Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
SUNLIGHT
Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients
- NCT04737187 ↗
- Completed
- Taiho Oncology, Inc.
- Focused
We haven't built an HCP commentary report on SUNLIGHT yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SUNLIGHT so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Randomized, Phase III Study Comparing Trifluridine/Tipiracil in Combination With Bevacizumab to Trifluridine/Tipiracil Monotherapy in Patients With Refractory Metastatic Colorectal Cancer (SUNLIGHT Study)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Refractory Metastatic Colorectal Cancer
- Interventions
- Trifluridine/Tipiracil; Bevacizumab
- Arms
- Trifluridine/Tipiracil + Bevacizumab · Experimental
- Trifluridine/Tipiracil · Active comparator
- Enrollment
- 492
- Primary outcomes
- Overall Survival (OS)
- Survival Probability at 6 Months
- Survival Probability at 12 Months
- Survival Probability at 18 Months
- Sponsor
- Taiho Oncology, Inc. with Institut de Recherches Internationales Servier
- Start
- Nov 25, 2020
- Primary completion
- Jul 19, 2022
- Results posted
- Yes
- Registry record
- NCT04737187 · updated Sep 24, 2024
Publications
linked from the registry- Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, Cruz FM, Wyrwicz L, Stroyakovskiy D, Papai Z, Poureau PG, Liposits G, Cremolini C, Bondarenko I, Modest DP, Benhadji KA, Amellal N, Leger C, Vidot L, Tabernero J; SUNLIGHT Investigators. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med. 2023 May 4;388(18):1657-1667. doi: 10.1056/NEJMoa2214963. PubMed 37133585
- Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, Wyrwicz L, Stroyakovskiy D, Liposits G, Bondarenko I, Modest DP, Amellal N, Tabernero J; SUNLIGHT Investigators. Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer. Future Oncol. 2024;20(36):2823-2832. doi: 10.1080/14796694.2024.2366100. Epub 2024 Jul 2. PubMed 38953855